Bugs as drugs: neglected but a promising future therapeutic strategy in cancer.

antitumor response attenuation bacteria-mediated therapy biofilms biosurfactants cancer therapy

Journal

Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629

Informations de publication

Date de publication:
Apr 2022
Historique:
pubmed: 10 2 2022
medline: 7 4 2022
entrez: 9 2 2022
Statut: ppublish

Résumé

Effective cancer treatment is an urgent need due to the rising incidence of cancer. One of the most promising future strategies in cancer treatment is using microorganisms as cancer indicators, prophylactic agents, immune activators, vaccines or vectors in antitumor therapy. The success of bacteria-mediated chemotherapy will be dependent on the balance of therapeutic benefit and the control of bacterial infection in the body. Additionally, protozoans and viruses have the potential to be used in cancer therapy. This review summarizes how these microorganisms interact with tumor microenvironments and the challenges of a 'bugs as drugs' approach in cancer therapy. Several standpoints are discussed, such as bacteria as vectors for gene therapy that shuttle therapeutic compounds into tumor tissues, their intrinsic antitumor activities and their combination with chemotherapy or radiotherapy. Bug-based cancer therapy is a two-edged sword and we need to find the opportunities by overcoming the challenges. Microbe-based cancer treatment strives to address urgent healthcare needs in patients experiencing difficult-to-treat cancers by using tumor-specific infectious microbes. Due to the ease of microbial culturing, microbes can be self-regenerating cancer therapeutics. Despite the fact that bacteria are usually believed to be the primary cause of cancer, the scientific literature has revealed exciting data indicating that bacteria might be efficient cancer prophylactic and therapeutic agents and ideal carriers for targeted cancer therapy. Advanced molecular engineering has recently been applied to bacterial therapy, resulting in increased efficacy with fewer adverse effects.

Autres résumés

Type: plain-language-summary (eng)
Microbe-based cancer treatment strives to address urgent healthcare needs in patients experiencing difficult-to-treat cancers by using tumor-specific infectious microbes. Due to the ease of microbial culturing, microbes can be self-regenerating cancer therapeutics. Despite the fact that bacteria are usually believed to be the primary cause of cancer, the scientific literature has revealed exciting data indicating that bacteria might be efficient cancer prophylactic and therapeutic agents and ideal carriers for targeted cancer therapy. Advanced molecular engineering has recently been applied to bacterial therapy, resulting in increased efficacy with fewer adverse effects.

Identifiants

pubmed: 35137604
doi: 10.2217/fon-2021-1137
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1609-1626

Auteurs

Mithoor Divyashree (M)

Nitte University Centre for Science Education & Research (NUCSER), NITTE (Deemed to be University), Paneer Campus, Deralakatte, Mangalore, 575018, Karnataka, India.

Shama K Prakash (SK)

K. S. Hegde Medical Academy, NITTE (Deemed to be University), Deralakatte, Mangalore, 575018, Karnataka, India.

Vankadari Aditya (V)

Nitte University Centre for Science Education & Research (NUCSER), NITTE (Deemed to be University), Paneer Campus, Deralakatte, Mangalore, 575018, Karnataka, India.

Alaa Aa Aljabali (AA)

Department of Pharmaceutics & Pharmaceutical Technology, Yarmouk University-Faculty of Pharmacy, Irbid, 566, Jordan.

Khalid J Alzahrani (KJ)

Department of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, Taif, 21944, Saudi Arabia.

Vasco Azevedo (V)

Department of Genetics, Laboratory of Cellular & Molecular Genetics, Ecology & Evolution, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, CEP, 31270-901, Brazil.

Aristóteles Góes-Neto (A)

Department of Microbiology, Molecular & Computational Biology of Fungi Laboratory, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, CEP, 31270-901, Brazil.

Murtaza M Tambuwala (MM)

School of Pharmacy & Pharmaceutical Science, Ulster University, Coleraine, Northern Ireland, BT52 1SA, UK.

Debmalya Barh (D)

Department of Genetics, Laboratory of Cellular & Molecular Genetics, Ecology & Evolution, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, CEP, 31270-901, Brazil.
Institute of Integrative Omics & Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur WB, 721172, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH